Browsing by Author "Atay, Didem"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Different Kinetics and Risk Factors for Isolated Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia
    (ELSEVIER SCIENCE INC, 2021-01-01) Hazar, Volkan; Ozturk, Gulyuz; Yalcin, Koray; Uygun, Vedat; Aksoylar, Serap; Kupesiz, A.; Bozkaya, Ikbal Ok; Karagun, Barbaros Sahin; Bozkurt, Ceyhun; Ileri, Talia; Atay, Didem; Kocak, Ulker; Karasu, Gulsun Tezcan; Yesilipek, Akif; Gokce, Muge; Kansoy, Savas; Kintrup, Gulen Tuysuz; Karakukcu, Musa; Okur, Fatma Visal; Ertem, Mehmet; Kaya, Zuhre; Gursel, Orhan; Yaman, Yontem; Ozbek, Namik; Antmen, Bulent; Tufekci, Ozlem; Albayrak, Canan; Aksoy, Basak Adakli; Sezgin, Gulay; Albayrak, Davut; Evim, Melike Sezgin; Zengin, Emine; Pekpak, Esra; Transpl, Turkish Pediat Bone Marrow
    Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most frequent cause of post-transplantation mortality. Isolated extramedullary (EM) relapse (iEMR) after HSCT is relatively rare and not well characterized, particularly in pediatric patients. We retrospectively analyzed 1527 consecutive pediatric patients with acute leukemia after allo-HSCT to study the incidence, risk factors, and outcome of iEMR compared with systemic relapse. The 5 -year cumulative incidence of systemic relapse (either bone marrow {[}BM] only or BM combined with EMR) was 24.8\%, and that of iEMR was 5.5\%. The onset of relapse after allo-HSCT was significantly longer in EM sites than in BM sites (7.19 and 5.58 months, respectively
  • Thumbnail Image
    Item
    Mesenchymal Stem Cell Treatment for Steroid Refractory Graft-versus-Host Disease in Children: A Pilot and First Study from Turkey
    (HINDAWI LTD, 2016-01-01) Erbey, Fatih; Atay, Didem; Akcay, Arzu; Ovali, Ercument; Ozturk, Gulyuz
    This study evaluated the efficacy of mesenchymal stem cells (MSCs) from bone marrow of a third-party donor for refractory aGVHD. We report the first experience using MSCs to treat refractory aGVHD in 33 pediatric patients undergoing allogeneic HSCT from Turkey. Totally, 68 doses of bone marrow derived MSCs were infused. The median dose of MSC was 1.18 x 10(6) cells per kg body weight. Overall, complete response (CR) was documented in 18 patients, partial response (PR) was documented in 7 patients, and no response (NR) was documented in 8 patients. The 2-year estimated probability of overall survival (OS) for patients achieving CR and PR/NR was 63.8\% and 29.4\%, respectively (p = 0.0002). While the cumulative incidence of transplant related mortality (TRM) at day 100 after first MSC infusion was 46.6\% in PR/NR patients, there was no any TRM at day 100 after first MSC infusion in CR patients (p = 0.001). Twelve patients developed chronic GVHD (cGVHD)